COR-1167 / Corteria Pharmaceuticals - LARVOL DELTA

First in class CRF2 receptor agonist COR-1167, reduces decompensation, improves exercise capacity, cardiac and renal function on top of Empagliflozin in the ZSF-1 rat model of worsening heart failure with preserved ejection fraction (AHA 2025) - "Urocortin-2 (UCN-2) peptide which is part of the corticotropin-releasing factor (CRF) family, is a paracrine CRF2 receptor agonist that protects heart and kidney function in various HF models and in HF patients. On a background of volume overload and Empa treatment, daily s.c. delivery of COR-1167 maintained CO, rapidly ameliorated decompensation and deteriorating heart and kidney function in ZSF-1 rats. Chronic CRF2 agonism with COR-1167 is a potential new therapy to treat patients with WHF and preserved ejection fraction."

Late-breaking abstract • Preclinical • Cardiovascular • Congestive Heart Failure • Glomerulonephritis • Heart Failure • KIM1

CRAFT-WHF: CRF2 Agonist for the Treatment of Worsening Heart Failure (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Corteria Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure